Plaque Psoriasis

UCB announced positive results from the phase 3 BE SURE study of bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis compared with adalimumab.

Adalimumab 0.8 mg/kg every other week was effective in a population of children and adolescents affected by moderate to severe plaque psoriasis, results of a real-life clinical experience show.

Bimekizumab (UCB), an investigational treatment for moderate-to-severe plaque psoriasis, met its two primary end points in a second phase 3 trial.

No differences in the risk for major cardiovascular events were found between etanercept, adalimumab, and ustekinumab in adult patients with moderate to severe plaque psoriasis following short- to medium-term exposure.

Differences in responses in patients who eventually achieved PASI improvement <50% and ≥50% could be differentiated as early as week 8, after two doses of tildrakizumab.

Results found that 82% of patients in the combined group achieved PASI 90 and IGA 0/1 at week 204.

Bimekizumab met both co-primary end points as well as key secondary end points demonstrating superior to ustekinumab and placebo at Week 16.

The proportion of patients who achieved at least 90% improvement from baseline in PASI after 16 weeks of treatment was 35% higher for risankizumab compared with adalimumab, showing that inhibiting the IL-23p19 pathway has set a new therapeutic benchmark.

Investigators found a number of benefits to subcutaneous methotrexate vs oral methotrexate for treatment and prophylaxis of chronic plaque psoriasis.